Method for predicting response to cancer immunotherapy by using dna methylation aberration in line-1
AssigneesPentamedix Co., Ltd., Korea Advanced Institute of Science and Technology
InventorsJung Kyoon CHOI, Kyeong Hui KIM, In Kyung SHIN, Seung Jae NOH, Dae Yeon CHO
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method for providing information for predicting a response to cancer therapy, comprising the step of obtaining information on a DNA methylation level of a long interspersed nuclear element-1 (LINE-1) subfamily from an isolated sample of a cancer patient, wherein the LINE-1 subfamily is at least one selected from the group consisting of LIPA12_5end, LIHS_5end, L1PA10_3end, LIP2_5end, L1PA11_3end, L1P2_5end, L1PA13_3end, L1PA11_3end, and LIP1_orf2.
Claims7
A method for providing information for predicting a response to cancer therapy comprising:
- obtaining information on a DNA methylation level of a long interspersed nuclear element-1 (LINE-1) subfamily from an isolated sample of a cancer patient, wherein the LINE-1 subfamily is at least one selected from the group consisting of LIPA12_5end, LIHS_5end, LIPA10_3end, LIP2_5end, LIPA11_3end, LIP2_5end, LIPA13_3end, LIPA11_3end and LIP1_orf2.
Dependencies are inferred from the claim text.